News round-up for 29 July – 2 August by DDW Senior Digital Content Editor Diana Spencer.

GLP-1 receptor agonists have dominated the headlines this week, with data revealed on new potential beneficial effects of treatment with semaglutide and dual receptor agonists like pemvidutide.

The top stories:

Semaglutide (Ozempic) found to treat smoking addiction

New research has linked semaglutide (the active ingredient in Wegovy and Ozempic) with improved smoking cessation.

GLP-1 receptor agonist slows Alzheimer’s cognitive decline

In new revelations about glucagon-like peptide-1 (GLP-1) drugs like Ozempic, a study has demonstrated the therapies could protect against dementia.

MHRA approves semaglutide to reduce risk of cardiovascular events

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication for semaglutide (Wegovy) to reduce the risk of overweight and obese adults suffering from heart attacks or stroke.

GLP-1/glucagon receptor agonist shows promise in liver disease

In a 12-week clinical trial, weekly doses of Altimmune’s pemvidutide resulted in up to 68.5% relative reduction in liver fat content (LFC), with up to 55.6% of subjects achieving LFC normalisation after 12 weeks of treatment.

Obesity drug competition expected to intensify by 2030

Viking Therapeutics’ dual GLP-1/GIP receptor agonist VK2735 could become a direct competitor to Eli Lilly’s Mounjaro/Zepbound (tirzepatide), predicts data analytics company GlobalData.